Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. KPRX
KPRX logo

KPRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kiora Pharmaceuticals Inc (KPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.180
1 Day change
1.87%
52 Week Range
4.180
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Kiora Pharmaceuticals Inc (KPRX) is not a good buy for a beginner, long-term investor at this time. The technical indicators are bearish, there are no strong trading signals, and the company's financial performance has significantly deteriorated. Additionally, there are no positive news catalysts or influential trading activity to support a buy decision.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 43.189, suggesting no clear trend. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 2.046, with resistance at 2.147 and support at 1.945.

Positive Catalysts

  • NULL. There are no recent news updates, no significant hedge fund or insider activity, and no influential trading activity.

Neutral/Negative Catalysts

  • The company's financial performance in Q3 2025 shows a significant decline across all key metrics, including revenue, net income, EPS, and gross margin. Technical indicators are bearish, and there is no recent positive sentiment or trading signals.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped by -100.79% YoY, EPS declined by -101.23% YoY, and gross margin fell by -100.00%. The financial performance indicates severe weakness.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target updates are available.

Wall Street analysts forecast KPRX stock price to rise
1 Analyst Rating
Wall Street analysts forecast KPRX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.140
sliders
Low
12
Averages
12
High
12
Current: 2.140
sliders
Low
12
Averages
12
High
12
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10
AI Analysis
2025-07-22
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10
AI Analysis
2025-07-22
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$10
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$10
2025-03-28
Reiterates
Strong Buy
Reason

People Also Watch